Conference Details
Panel Discussion on Biopharmaceutical Commercial Launches
Wednesday, January 5th at
https://wsw.com/webcast/lifesci3/panel1/2377650
Monday, January 10th -
BIO Partnering at JPM
Monday, January 10th -
About Trevena
For more information, please visit www.Trevena.com
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the
For more information, please contact:
Investor Contact:
Managing Director
daniel@lifesciadvisors.com
(617) 430-7576
PR & Media Contact:
Associate Vice President
Sasha.Bennett@clydegroup.com
(239) 248-3409
![](https://ml.globenewswire.com/media/ZDJmZTkxOTAtNjU3MC00Yzk1LTlhNWItNjU0Y2E0MjE4NWI1LTEwMTY2MDc=/tiny/Trevena-Inc-.png)
2022 GlobeNewswire, Inc., source